Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cancer
immunotherapy |
| gptkbp:advantage |
gptkb:CAR-T_therapy
|
| gptkbp:benefit |
off-the-shelf availability
lower risk of cytokine release syndrome lower risk of graft-versus-host disease |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:derivedFrom |
induced pluripotent stem cells
peripheral blood umbilical cord blood NK cell lines |
| gptkbp:firstClinicalTrialYear |
2019
|
| https://www.w3.org/2000/01/rdf-schema#label |
CAR-NK therapy
|
| gptkbp:mechanismOfAction |
release of cytotoxic granules
antigen-specific cytotoxicity secretion of cytokines |
| gptkbp:potentialLimitation |
short in vivo persistence
manufacturing challenges |
| gptkbp:studiedBy |
gptkb:MD_Anderson_Cancer_Center
various academic institutions solid tumors hematological malignancies |
| gptkbp:target |
tumor cells
|
| gptkbp:uses |
gptkb:natural_killer_cells
chimeric antigen receptor |
| gptkbp:bfsParent |
gptkb:NK_cell
|
| gptkbp:bfsLayer |
8
|